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ABSTRACT
Introduction
Epilepsy is one of the most common chronic neurological disorders requiring prolonged treatments and drugs.
According to The World Health Organization (WHO), epilepsy is one of those serious brain disorders that affect not only
the individual but has a deep impact on the family and society in general. Approximately 50 million people are affected
with epilepsy around the world36, though proper epidemiological studies do not exist for Pakistan it is estimated that
the prevalence of epilepsy is 9.99/1000. Highest prevalence is seen in people younger than 30 years of age, i.e. about
2 million people and 1/10th of the world burden of epilepsy is in Pakistan! The guidelines available in developed
countries are gauged in a setting where epilepsy care is provided by epileptologists/neurologists. In Pakistan the
scenario is different, there is only one neurologist for 1.4 million (14lac) population contrast to US where one
neurologist for 26 thousand people 29. So there is a desperate need to adapt to alternate guidelines with strategies
to provide epilepsy management at a primary care level and to standardize epilepsy care on a National level.
Methods
To form these guidelines we reviewed and adopted from many different available guidelines mainly
1.
Local adaptations of the WHO recommendations4
2.
Modification of the ILAE treatment guide lines: evidence based analysis of AEDs 200611
3.
Updated ILAE evidence review of AEDs special report 201312
4.
Existing guidelines in other low income countries13-15
5.
NICE, AAN, AES recommendations.17-21
Results
These guidelines consist of
1.
2.
3.

The universally ILAE accepted definition and classification of epilepsy and Epileptic syndromes with A step wise
approach to a patient with seizures and epilepsy in Pakistan.
Tables Selecting the right drug with evidence based references keeping in mind the cost and availability in Pakistan.
AED selection in special populations e.g. women20, children17 and elderly
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4.
5.

Status Epilepticus Protocol
Algorithms and tables for easy access

brain disorders that affect not only the individual but
has a deep impact on the family and society in general.
Approximately 50 million people are affected with
epilepsy around the world,4 and this number will
increase with the new definition. Though proper
epidemiological studies do not exist for Pakistan it is
estimated that the prevalence of epilepsy is
9.99/1000. Highest prevalence is seen in people
younger than 30 years of age5. That is: about 2 million
people and 1/10th of the world burden of epilepsy is in
Pakistan. The recent estimates of population of Pakistan
exceed 180 million, whereas the total number of trained
neurologists in Pakistan is estimated to be 135 (Pakistan
Society of Neurology Directory 2013)5. Based on the
available data, the estimated 2 million people suffering
from epilepsy in Pakistan, makes it one neurologist
available for every 15200 sufferers of epilepsy with only
few trained in epilepsy. Despite efforts to create
awareness there remains a wide treatment gap and
misconception. The guidelines available in developed
countries are gauged in a setting where epilepsy care is
provided by epileptologists/ neurologists. In Pakistan it is
a different scenario, there is only one neurologist for 1.4
million population contrast to US where one neurologist
for 26 thousand people4. So there is a desperate need to
adapt to alternate guidelines with strategies to provide
epilepsy management at a primary care level and to
standardize epilepsy care on a National level. The
primary care physicians in civil hospitals and
dispensaries, and general practioners (GPs), form the
crux of health care in Pakistan and therefore see most of
the PWE. Unfortunately neurology rotation is not a
mandatory in undergraduate training thus most lack the
information and skill needed for proper epilepsy
diagnosis and management. In 2011, WHO mental
health Gap Action Programme (mhGAP) released
evidence based epilepsy care guidelines for use in low
and middle income countries4. These guidelines provide
a crudePerforma that requires local adaptation for use
within individual countries. The guidelines state “For
effective implementation and sustainability, the sense
of ownership and empowerment must be transferred
from the global health authorities to the local people.
Socio-cultural and financial barriers that impede the
implementation of the guidelines should be identified
and ameliorated.4

(Due to the limitation of space , points 3 and 4 will
be published subsequently)
CONCLUSION
The primary scope of these guidelines is to provide a
concise practical management plan which considers the
role of AEDs especially their judicial useThese guidelines
hope to provide the physicians treating epilepsy patients
with a step wise cost effective approach to the patient
with epilepsy. A separate guideline to classification and
diagnosis is also available, and the guidelines in entirety
are also available on line at the Pakistan Society of
Neurology website.
Guidelines Introduction
Epilepsy is one of the most common chronic neurological
disorders requiring prolonged treatments and drugs. It is
a disorder that is widely misunderstood and carries a
vicious stigma. Epilepsy comprises a vast group of
disorders and syndromes with one common symptom,
“The Seizure”. For the purpose of these guidelines we
have integrated the International League Against
Epilepsy (ILAE) definitions of seizures and epilepsy. There
is a vast array of literature and guidelines that exist in
developed countries for over a decade. These have been
reviewed and compiled and modified to suit the Pakistani
population and socioeconomic status. These guidelines
hope to help improve medical decision making in
Pakistan while treating the patient with epilepsy (PWE)
THE NEED FOR NATIONAL GUIDELINES FOR
EPILEPSY IN PAKISTAN:
Epilepsy has varied etiologies and affects all age
groups, but the vast majority of cases are treatable with
Anti Epileptic Drugs (AEDs) most of which are easily
available. However knowledge about epilepsy and its
care is extremely low. The majority of people with
epilepsy (PWE) are treated inadequately or
inappropriately. According to The World Health
Organization ( WHO), epilepsy is one of those serious
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Table 1: Factors to consider while developing National guidelines.
Factor

Developed country

Developing country like Pakistan

Gross National income

> USD 3036

< USD 565

Access to Health care

Primary care for all with
established referral systems

Limited to
very basic
primary
care

Health care funding

National programs and private
insurance systems

Often ill funded
rely on donors or
volunteers. No
set system of
insurance

Cultural perception of seizures

Biomedical model

Traditional medicine,
spiritual approach,
contagion belief
common

Common Epilepsy etiologies

Ideopathic, neoplastic cerebrovacular

Post infectious,
antenatal,
post traumatic

Socio-cultural attitudes towards
epilepsy

At lease social presentation of neutrality

Overt negative
public perception,
stigmatization, and
discrimination common

Treatment gap

<20%

70-94%

ARIABLES AFFECTING SELECTION OF AEDS IN PAKISTAN
Epidemiological studies of prevalence and incidence reviewedare problematic in Pakistan due to lack of proper data
collection teams and resources. Data concerning seizure type, etiology, and severity of seizuresare contrasted with those
from developed countries. Sociocultural aspects of epilepsy have been poorly studied, and yet are fundamental to
effective medical management. Thus the principles and success of treatment in Pakistan may differ considerably from
developed countries. The principles of drug therapy may not be understood by patients, and the supply of drugs is often
erratic; and these are major reasons for poor compliance with treatment. Therapy need to be prioritized to cost
effectiveness, requiring a cheaper drug eg.phenobarbital to be tried as first line contrary to international guidelines.
Computations of treatment gap figures in three developing countries suggest that between 80-94% of patients with active
epilepsy are not receiving anticonvulsant therapy, cost and cultural belief sare two of the main factors.
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Table 2: Factors affecting AED selection
AED-speciﬁc variables

Patient-speciﬁc variables

Nation-speciﬁc variables

Seizure type or
epilepsy syndrome
speciﬁc efﬁcacy or
effectiveness
Dose-dependent
adverse effects
Idiosyncratic reactions
Chronic toxicities
Teratogenicity
Carcinogenicity
Pharmacokinetics
Interaction potential
Formulations

Genetic background
Age
Gender
Comedications
Comorbidities
Insurance coverage
Ability to swallow
pills/tablets

AED availability
AED cost
Insurance coverage
Socio-cultural issues
Compliance

Q8-Q9: Status Epilepticus in Adults and children (protocols)
Q10-Q13: Access to medications, direct and indirect
costs, co-morbid conditions, preventable causes
Q14-Q15: Alternate Therapies, diet.
Q16: Epilepsy surgery.
Q17-Q19: Lifestyle, Career choices, Driving.
Q20-23: Epilepsy Diaries, lockets, keychain or bracelets,
Help line.

To form these guidelines we reviewed and adopted from
many different available guidelines mainly.
1)
2)
3)
4)

Local adaptations of the WHO recommendations (4)
Modification of the ILAE treatment guidelines:
based analysis of AEDs 2006 (11)
Updated ILAE evidence review of AEDs special
report 2013(12)
Existing guidelines in other low income countries
(13’14’15’16)

5)
6)
7)
8)

Monotherapy Guideline questions:

NICE guidelines,(17)
AAN practice parameters, (18)
AES recommendations.(19)
A multitude of literature to support our selection
and recommendations (20-43)

Q1-Q3: Patients (adults/elderly/children) with partialonset seizures
Q4-Q5: Patients (adults/children) with generalizedonset tonic-clonic seizures
Q6: Children with idiopathic localization-related
epilepsies and syndromes (BECTS).
Q7-Q8: Children with idiopathic-generalized epilepsies
(CAE, JME).
Q9: Special Issues related to Women.
Q10: Considerations in Elderly and Multiple handicapped

Management Guidelines:
QUESTIONS ADDRESSED
Q1-Q3: AEDs Initiation of therapy/Mono therapy;
Adjuvant therapy; Cessation of therapy
Q4-Q7: Women (fertility, contraception, conception,
pregnancy, lactation, teratogenicity), Children, elderly
differences

Questions 6-10 are discussed in the special population
subset of these guidelines not published in this edition.

A person is considered to have epilepsy if they meet any of the following conditions:
At least two unprovoked (or reflex) seizures occurring greater than 24 hours apart.
One unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least
60%) after two unprovoked seizures, occurring over the next 10 years.
Diagnosis of an epilepsy syndrome
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(Table 4)

For Classification and Diagnosis guidelines see Appendix A
MANAGEMENT OF EPILEPSY

Definitely:
Possibly:
With structural lesion like Unprovoked seizure
Brain tumor, AVM,
Infection,
Probably not:
Without structural lesion: alcohol withdrawal
h/o Epilepsy in sibling
Drug abuse
EEG with definite pattern. Sz with acute illness
Prior but remote sz prior post impact seizure
neurological hist.
A benign epilepsy
Todds post ictal paresis syndrome.
statusepilepticus at onset. Excessive sleep deprivation.

Non-pharmacological Management:
Once diagnosis is made patient and family members
need to be counselled empathically. Since the disease
still carries a strong stigma, confidentiality needs to be
maintained at all steps, and the condition should be
discussed with any family member with consent of the
PWE.
•
•
•
•

Establish the diagnosis
Education/ counselling
Address psychosocial issues
Lifestyle modifications

AED should be selected according to suitability of the
patient, type of epilepsy etc.
Table 3 shows factors determining suitability.

Patients need counselling regarding the
• Disease
• Drognosis
• Need for medication
• Compliance
• Life style

Table 5
Factors determining AED suitability include:

Life style modification includes
• Adequate sleep - early to bed early to rise
• Change in job e.g. occupation, driving, swimmers,
boxers, airplane pilots etc.
• Avoidance of alcohol, stimulants, energy drinks,
gutka, JM, etc.
• Stress reduction — specific techniques, Yoga,
meditation, early morning walks
• Adequate diet – high protein. Low carbohydrate,
Vit. D, B rich diet
• Joining support groups
• Avoid social isolation

seizure type and/or epilepsy syndrome;
childbearing potential;
the presence of comorbidity;
individual and/or carer preferences;
the presence of contraindications to the drug;
potential interactions with other drugs;
potential adverse effects
the licensed indication of the drug.
Cost of AED
Patients socio-economic status
Age
Compliance
AED availability
Adult lifestyle

Pharmacological treatment of epilepsy
The mainstay of treatment for epilepsy is antiepileptic
drugs (AEDs) taken daily to prevent the recurrence of
epileptic seizures. It is important that the treatment
strategy and suitability of the AED is determined by the
prescriber keeping the individual with epilepsy and
thecarer informed before drug therapy is started.

The diagnosis of epilepsy needs to be critically evaluated if
events continue despite an optimal dose of a first line AED.
Before combination therapy is considered, PWE should be
given a trial of at least 2-3 appropriate monotherapy
regimens, with caution during the transition.

When to Start AEDs after first seizures

General Recommendations:

Whether to treat first seizure is controversial studies show
16-62% recur within 5 years, Relapse rate is reduced by
antiepileptic drug treatment, and it is now recommended
that since Neurological abnormalities, abnormal imaging,
abnormal EEG or family history increase relapse risk these
patients should be treated after first seizure.
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2)

Caution is needed during the changeover period,
with the second drug titrated and the first drug
decreased gradually.
3) It is recommended that combination therapy
(adjunctive or ‘add-on’ therapy) should only be
considered when attempts at monotherapy with
AEDs have not resulted in seizure control.
4) If trials of combination therapy do not bring about
worth while benefits, Diagnosis should be revisited
and treatment should revert to the regimen with
best control providing efficacy in reducing seizures
and tolerability of side effects.
5) Refer to specialist for phase II evaluation and
Epilepsy surgery, classify and diagnose cause of
refractory epilepsy, epileptic or non-epileptic fits.
6) If an AED has failed because of adverse effects or
continued seizures, a second drug should be
started (which may be an alternative first-line or
second-line drug) and built up to an adequate or
maximum tolerated dose and then the first drug
should be tapered off slowly.
7) If the second drug is unhelpful, either the first or
second drug may be tapered, depending on
relative efficacy, side effects and how well the
drugs are tolerated before starting another drug.
8) It should be recognised that some PWEs (through
their families in some instances) may choose not
to take AED therapy following a full discussion of
risks and benefits. Reason should be sought and
addressed accordingly. Treatment should be
insisted upon if risk of recurrence is high as
described in table 3.
9) Treatment of a first unprovoked seizure reduces
the risk of recurrence in the short-term.
In children, treatment of a first unprovoked seizure
does not alter the long-term prognosis for seizure
remission.
10) AED therapy should only be started once the
diagnosis of epilepsy is confirmed, except in
exceptional circumstances that require discussion
and agreement between the physician and the
PWE and/or carers as appropriate.
11) Continuing AED therapy should be planned by the
physician. It should be part of the PWE agreed
treatment plan, which should include details of
how specific drug choices were made, drug

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

12)

13)

14)
15)
16)

17)
18)
19)

20)

21)
22)

52

dosage, possible side effects, and action to take if
seizures persist.
When possible, choose which AED to offer on the
basis of the presenting epilepsy syndrome. If the
epilepsy syndrome is not clear at presentation,
base the decision on the presenting seizure
type(s).
Consistent supply to the PWE of a particular
manufacturer’s AED preparation is recommended.
Different preparations of some AEDs may vary in
bioavailability or pharmacokinetic profiles and care
needs to be taken to avoid reduced effect
orexcessive side effects.
Where partial seizures are suspected prefer
sodium channel blockers as first line AEDs (see fig 1)
Where generalized seizure syndromes are suspected consider broader spectrum AEDs (see fig 1)
Phenobarbitone is a broad spectrum efficacious
AED that is easily available in Pakistan at minimal
price, therefore should still be considered as first
line therapy where affordability is an issue as risk
of seizures outweigh the long term side effects.
Phenobarbitone should be offered where
compliance due to cost is suspectected.
If using carbamazepine, check LFTs.
When prescribing sodium valproate to women nd
girls of present and future childbearing potential,
discuss the possible risk of malformation and
neurodevelopmental impairments in an unborn
child, particularly with high doses of this AED or
when using as part of polytherapy. Vit B, folate
and calcium supplements should be added.
Lamotrigine should be administered with caution
and slow titration when given as monotherapy and
with even slower titration when combined with
inducers like valproate to avoid the risk of
idiosyncratic reactions like Steven Johnson’s
syndrome and toxic epidermolysis. All patients
should be counseled and warned to stop
medication and contact the physician immediately
if any rash appears.
Levitiracetam should be given with neuropsychiatric issues in mind and pyridoxine supplement.
Maintain a high level of vigilance for treatment
emergent adverse effects (for example, bone
health issues, blood dyscrasias, and neuropsychiatric issues)
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23) If management is complicated, PWE should be
referred to specialist.
24) The prescriber must ensure that the PWE and/or
carers as appropriate are fully informed about
treatment including action to be taken after a
missed dose or after a gastrointestinal upset.
25) Regular blood test monitoring in PWE is not
recommended as routine, and should be done only
if clinically indicated or non-complance is suspected as below.
Examples of blood tests include:
Before surgery – clotting studies in those on
sodium valproate. For Patients on enzyme inducing
AEDs: CBC, Electrolytes, LFTs, Vit D levels, every
1-2 years. Test for serum amino acids, TSH and
urine for organic acids in all children with neonatal
non-infectious seizures and refractory seizures.
26) Asymptomatic minor abnormalities in test results
are not necessarily an indication for changes in
medication.
27) Every patient when stable should still have a 6
monthly follow-up to ensure compliance, and
review treatment plan and side effects.
28) For uncontrolled patients treatment should be
reviewed at regular intervals so PWE are not
maintained for long periods on treatment that is
ineffective or poorly tolerated, when in doubt early
referral is more cost effective
29) Compliance can be optimized with the following:
Educating PWE and their families and/or carers in

the understanding of their condition and the
rationale of treatment
Reducing the stigma associated with the condition
Using simple medication regimens
Positive
relationships
between
healthcare
professionals PWE, and their family.
SMS bulk reminder module
30) The risks and benefits of continuing or withdrawing
AED therapy should be discussed with PWE and/or
carers as appropriate, who have been seizure free
for at least 2 years At the end of the discussion,
they should understand their risk of seizure
recurrence off treatment. This discussion should
take into account details of the PWE’s epilepy
syndrome, prognosis and life style.
31) When AED treatment is being discontinued in PWE
who has been seizure free, it should be carried out
slowly (at least 2-3 months) and one drug should
be withdrawn at a time.
32) Particular care should be taken when withdrawing
benzodiazepines and barbiturates (may take up to
6 months or longer) because of the possibility of
drug- related withdrawal symptoms and/or seizure
recurrence.
33) PWE and carer should be counseled whereby if
seizures recur the last dose reduction is reversed
and medical advice is sought.

Table 6: List of available AED’s worldwide vs those available in Pakistan with abbreviations, dosage, indication and
common side effects.

Usual Starting

Titrated Up or

Usual Maximum

Common Side

Dose

Down By

Daily Dose

Effects

Acetazolamie
(AZM)

250 mgs

250mgs every
1/52

1000mgs daily
In divided doses

GIT Dist.
U&E Dist
† urine output

Adjunctive for all
sz types
especially drop
attacks

Carbamazepine
(CBZ)

100-200 mgs
1-2 times daily
2-3mg/kg/day

100 mgs every

2000 mgs daily
In divided doses
10-20mg/kg/day

GIT Dist.
#Rash
Hyponatremia
agranulocytosis

Mono/adjunctive
therapy. Worsens
myoclonic and
absence seizures

Drowsiness

1/52

Up to 60 mgs
daily

Adjunctive for all
sz type

0.5 mgs

8 mgs daily

Drowsiness

Mono/adjunctive

Medication

bd

Clobazam (CBZ) 5-10 mgs daily

Clonazepam
(CLB)

0.5 mgs bd

1/52
5-10 mgs every
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Diazepam

5-10mgs daily

2.5-5mgs

30mgs per day

Drowsiness

Prolonged/cluster
seizures

250 mgs bd

250 mgs every

2000 mgs daily

GIT Dist.
Drowsiness

Mono/adjunctive
for absence szs

300 mgs every

3600 mgs daily

1/52

In divided doses

Liver Failure and
aplastic anemia
rare risk 1:5000

Adjunctive for all
Szs types which
have failed all
other AEDs. Used
under strict
specialist
supervision

200-300 mgs

3600 mgs daily

every 1/52

In divided doses

GIT Dist.
Weight Gain

Mono/adjunctive
for partial onset
szs +/- sec gen

Nausea,
dizziness,
somnolence,
headache

Adjunctive for
partial onset szs
+/- sec gen

#Rash
Insomnia GIT
Dist. Headache
Tremor with VPA

Mono/adjunctive
for all sz types

Psychosis Low
Mood GIT

Mono/adjunctive
for all sz types

(DZP)
Ethosuximide*
(ESM)
**Felbamate

Gabapentin

1/52
300 mgs tds

200-300 mgs tds

(GBT)
Lacosamide

Initially 50mgs bd

Increase weekly

200mgs bd or

(LCM)

1-2mg/kg/day

by 50mg bid

6-9mg/kg/day

Lamotrinine

25 mgs od

25 mgs every

500 mgs daily

25 mgs alternate

week In children

Children

days When on

with VPA 1-5

10mg/kg/day

VPA To a target

mg/kg/day

dose of 100mgs

Without VPA

BD Children

2-10mg/kg/day

(LTG)

0.5mg/kg/day
Levetiracetam

250 mgs bd

250-500 mgs

3000 mgs daily

(LEV)

250mgs od if

every week

(1.5g bd)
20-60mg/kg/day

Adjunctive
therapy
10mg/kg/day

Lorazepam

1-2 mgs daily

1-2 mgs

4 mgs daily

Drowsiness
Dependence

Adjunctive for all
sz types Rescue
use.

Midazalom

10 mgs daily

N/A

20 mgs

Drowsiness

For prolonged or
clusters of all szs.
Rescue use
Status Epilepticus

Oxcarbazepine

Initially 300mgs

Increased

2400 daily

(OXC)

twice daily

according to

In divided doses

Encephalopathy
Neutropenia

Mono/adjunctive
for partial onset
Szs +/- sec gen

(LZP)
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5-8mg/kg/day

response in steps

5-15mg/kg/day

Hyponatremia
*Rash

Mono/adjunctive
for all sz types
Status Epilepticus

of up to 600mgs
daily at weekly
intervals
Phenytoin

150-300mgs

Increased

Usual dose is

(PHT)

daily 5mg/kg/day

gradually as

200-500mgs

necessary (with

daily10-15mg/kg/

plasma phenytoin

day

GIT Dist.
Gingival Hypertrophy Hirsutism
*Rash

180 mgs daily

Drowsiness

Mono/adjunctive
for all sz types
Status Epilepticus

600 mgs daily
In divided doses

Weight gain

Adjunctive for
partial onset szs
+/- sec gen

1500 mgs daily
In 2 divided
doses

Drowsiness

Mono/adjunctive
for all sz types

concentration
monitoring
Phenobarbitone

30 mgs daily

(PB)
Pregabilin

15 mgs every
month

Initially 25mgs bd

50mgs every
1/52

Primidone*

Initially 125mgs

Increased by

(PMD)

at bed time

125mgs every 3
days to 500mgs
daily in 2 divided
doses (250mgs
bd), then
increased
according to
response by 250
mg s every 3 days

Rufinamide*

200 mgs BD daily

200 mgs every
1/52

1600 mgs BD
daily

GIT Dist.
Dizziness, fatigue

Adjunctive for
Lennox – Gastaut

Tiagabine*

5mgs bd

5-10mgs
every 1/52

30-45mgs daily
(doses above 30
mgs given in 3
divided doses)

Diarrhoea
Dizziness
Nervousness

Adjunctive for
partial onset szs
+/- sec gen

Topiramate

25 mgs daily

(TPM)

1mg/kg/day

25 mgs every
1/52

400mgs daily
(mono) In 2
divided doses
800mgs
(adjunctive) In 2
divided doses
( 6-9 mg/kg/day)

Weight Loss
Renal Calculi
Word Finding
Difficulties
Pins and needles

Mono/adjunctive
for all sz types

Valproate

300 mgs bd

(VPA)

5mg/kg/day

100-250 mgs
every week

3000 mgs daily
15mg/kg/day

Weight Gain
Tremor, hair loss
Liver Toxicity

Mono/adjunctive
for all sz types

(TGB)
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infants

Teratogenecity

10mg/kg/day
children
***Vigabatrin

500 mgs bd

(VGB)

20-50mg/kg/day

Zonisamide*

50 mgs daily or

(ZNG)

25mg bd.
1-2mg/kg/day

Increased
according to
response in steps
of 500mgs at
weekly intervals

3000 mgs daily
50-150mg/kg/day

Increased after 7
days to 100mgs
daily in 2 divided
doses then
increased if
necessary by
100mgs weekly

500 mgs daily
8-12mg/kg/day

Adjunctive for
partial onset szs
+/- sec gen
Monotherapy for
Wests syndrome

Weight loss
Ataxia
Renal Calculi

Adjunctive for
partial onset szs
+/- sec gen

AED INTERACTIONS

Not available in Pakistan or difficult to get
**Felbamate - Patients are usually electively admitted
when initiating this AED due to the incidence of fatal
liver failure and aplastic anaemia, for routine lab
observation.
***Vigabatrinl - Its use is restricted to whom all other
combinations are inadequate or not tolerated. It must
only be initiated by a Neurologist. All patients must have
visual field testing prior to commencement and every
6/12 thereafter.
# Rash All AEDs carry the risk of rash, however the
drugs highlighted as Rash carry a risk of Stevens Johnsons Syndrome.
• Enzyme inducers and affect the metabolism of other
drugs, for example Oral Contraceptives; women need to
be alerted of this interaction.
weak enzyme inducers and may affect the metabolism
of other drugs at high doses.
• Signs and Symptoms of Toxicity: vary from drug to
drug however the following may indicate possible
toxicity: Diplopia, blurred vision, unsteady gait,
excessive tiredness, new onset of dizziness.
• GIT Dist may manifest as anorexia, nausea, vomiting
dyspepsia, constipation, diarrhoea or any s/s of GI
disturbance Interactions between antiepileptic drugs
are complex and may enhance toxicity without a
corresponding increase in antiepileptic effect.
Interactions are usually caused by hepatic enzyme
induction or hepatic enzyme inhibition. These
interactions are highly variable and unpredictable.
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Hyperkinesia,
insomnia,Visual
field constriction
in 30% of
patients

Some common interactons between antiepileptic drugs
and non-antiepileptic drugs are listed below in table 7.
For a full list consult the PDR Summary of Product
Characteristics for each drug.
Note
Enzyme inducing AED’s increase the rate of
metabolism of Warfarin and The INR should be
monitored carefully when an enzyme AED is added
or discontinued.
Aspirin enhances valproate and phenytoin effects.
Antibiotics, macrolides (clarithromycin/erythromycin) increase the plasma concentration of carbamazepine and inhibit the metabolism of phenytoin.
Erythromycin possibly inhibits the metabolism of
valproate.
Meropenam, reduces plasma concentrations of
valproate.
Rifamycins accelerate phenytoin metaboism.
Analgesics, NSAIDs enhance the effects of
phenytoin.
Estrogens, enzyme inducing drugs accelerate
metabolism of Estrogens reducing contraceptive
effects. Estrogens reduce lamotrigine levels.
Plasma concentration of lamotrigine increased by
valproate.
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Table 7. Examples of important Drug interactions
Agents

General interactions

Agents that may
increase plasma levels

Agents that may
decrease plasma
levels

Carbamazepine

The simultaneous
administration of other
liqu- id medicines with
CBZ suspension can
cause rubbery precipitate
in stool. Coadministration with
lithiumcan neurotoxic
SE. Other AEDs may
alter thyroid functions.
es efficacy of hormonal
contraceptives.

CYP 3A4 inhibitors
Propoxiphene,
Vigabatrin, VPA,
protriptyline, loxopine,
sertraline, ritonavir,
nafimidone, isoniazid,
verapamil, ketoconazole,
cimetidine, flunerazine,
viloxazine, macrolides,
diltiazem

CYP 3A4 inducers,
felbamate, PHT,
mefloquin

Clonazepam

CNS depressants,
MAOIs, TCAs and some
anti convulsants may
increase depressant
effects of CNZ.
With VPA in Absence
seizures can induce
absence status!

CYP 3A inhibitors
Azole antifungals,
cimetidine

CBZ

Divalproate Sodium,
Valproaci acid

Drugs that elevate
expression of hepatic
enzymes increase the
clearance of valproate. It
increases free levels of
warfarin

Asprin, felbamate,
macrolides especially
clarithromycin

Cholestyramine,
meropenum, CBZ, PHT,
PB, rifampin. Primidone,
TPM

Phenytoin

Needs caution with other
albumin binding drugs,
PB, VPA, have
un-predictable effect on
levels.Antacids with
calcium
inhibitsabsorption. TCAs
risk for Sz.

CYP inhibitors, Azoles,,
trimethoprim,
chloramphenicol,
isoniazid, disulfiram,
phenylbutazone,
cimetidine, SSRI,
felbamate, TPM, CBZ,
ranitidine, ibuprofen,
amiodrone, diltiazem.

CYP inducers, Rifampin,
doxorubicin, VPA,
vigabatrin.

Fig 1: Mechanisms of action of antiepileptic drugs modified from j. physiology 2006
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Modified from j. primary psych 2005
Initiation of AEDs Drug choice with seizure type:
Treatment (Monotherapy) of patients with newly
diagnosed focal (partial, complex partial and
secondarily generalized) seizures:
A)

3)
4)

Adults with focal(partial) onset seizures (ILAE 2013)

RECOMMENDATIONS
1)

2)

Offer CBZ/ OXC or PB (where cost is an issue) as
first line treatmentas firstline treatment to patients
with newlydiagnosed focal seizures.
Offer LTG,PHT, OXC or VPA if CBZ and PB are

unsuitable or not tolerated. If the first AED tried is
ineffective, offer an alternative from these 5 AEDs.
(Be aware of the teratogenic risks of sodium
valproate and idiosyncratic rash of lamotrigine )
Consider adjunctive treatment if a second
well tolerated AED is ineffective
If adjunctive treatment is ineffective or not
tolerated, discuss with, or refer to, an epilepsy
specialist or neurologist. Other AEDs that may be
considered by the epilepsy specialist are
eslicarbazepine
acetate
(ECA),
clobazam,
lacosamide, phenytoin, pregabalin, tiagabine,
vigabatrin and zonisamide. Carefully consider the
risk benefit ratio when using vigabatrin because of
the risk of an irreversible effect on visual fields.

Table 8. Medication Selection In Patients with Focal onset seizures or symptomatic lesion related Epilepsies.
1st line AEDs

2nd Line AEDs

3rd Line AEDs

Carbamazepine CBZ

Levitiracetam LEV

Clonazepam CNZ

Phenytoin PHT

Valproate VPA

TiagabinTGN*

Oxcarbazepine OXC

Topiramate TPM

EsilCarbazepine Acetate ECA*

Lamotrigine LTG

Gabapentine GBP

ZonisamideZNS*

Phenobarbitone PB

Lacosamide LCM

Perampanel*
Clobazam CLB
Ruﬁnamide*
Vigabatrin

* Not av ai l abl e i n P a ki sta n

Table 9. Focal Seizures AED Selection guide by seizure type
Clinical Situation

Simple Partial Sz

Complex Partial Sz

Secondary generalized

Initial Monotherapy

CBZ
OXC
PHT
LTG

CBZ
OXC
PHT
LTG
LEV
ZNS

CBZ
PHT
OXC
LTG
VPA
LEV
ZNS

Pharmacological management(monotherapy) of
Adults with newly diagnosed Generalized Epilepsy
Syndromes (IGE).

controlled trials) for adults with GTC seizures implies a
marked deficiency in published studies. No AED has
reached the highest level of evidence (level A and B) for
efficacy. VPA, LTG,TPM, OXC, PB, PHT, TPM, and CBZ
are possibly level C, and GBP, LEV, and VGB are

The absence of class I and II RCTs(randomized
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potentially level D efficacious/effective as initial
monotherapy for adults with newly diagnosed or
untreated generalized onset tonic-clonic seizures. Class
IV evidence suggests that CBZ and PHT and other
sodium channel blockers may precipitate or aggravate
generalized onset seizures. (ILAE updates 2013).

Table 11. Idiopathic Generalized Epilepsy:
Medication Selection
AED selection
Initial
monotherapy
2nd
Monotherapy
if VPA failed
2nd
Monotherapy
if LTG/LEV failed

RECOMMENDATIONS
1)

2)

3)
4)

5)

Offer sodium valproate as firstline treatment to
adults
with
newly
diagnosed
GTCs.
(Be aware of teratogenic risks of sodium valproate
in women of child bearing age)
Offer lamotrigine if sodium valproate is unsuitable.
If the person has myoclonic seizures or is
suspected of having juvenile myoclonic epilepsy
(JME), (be aware that lamotrigine may exacerbate
myoclonic seizures. Be aware of idiosyncratic
reaction of lamotrigine by slow escalation)
Consider levitiracetamand Phenobarbital in
patients where VPA and LTG are not suitable.
Offer clobazam, CBZ, OXC and TPM as adjunctive
treatment to adults with GTC seizures if first line
treatments as above are ineffective or not
tolerated. (Be aware of the risk of exacerbating
myoclonic or absence seizures with CBZ and OXC)
If there are absence or myoclonic seizures, or if
JME is suspected, do not offer carbamazepine,
gabapentin, oxcarbazepine, phenytoin, pregabalin,
tiagabine or vigabatrin.

2nd line

3rd line

VPA

TPM

CNZ

LTG#

ZNS*

CBM

TPM

LEV

GBP

LEV

PB

CBZ#

PHT#

OXC#

LEV
VPA
ESM
ZNS
LTG

TPM
LEV
VPA
ZNS

The ketogenic diet (KD) is a high fat, low carbohydrate
and protein diet designed to mimic the biochemical
response of the body to starvation when ketone bodies
become the main fuel for the brain’s energy demands
(Hartman 2008)It has long been used in the treatment
of refractory epilepsy in children, although the exact
mechanism of action is unclear. The KD diet was initially
reported for use in epilepsy in 1921 (Wilder 1921). The
initial diet used was the classical ketogenic diet, based
on the ratio of fat to carbo-hydrate (with protein), of 3
or 4:1. Later an alternative was suggested using
triglyceride oil as a supplement, the Medium chain
Triglyceride (MCT) Diet (Huttenlocher et al 1971).
These diets have to be carefully administered with the
aid of a dietician.
•
There is no evidence of efficacy of ketogenic
diet in adults.
•
50% efficacy range is achieved in children.
•
Recommended in refractory epilepsies in
children where multiple regimens of AEDs
proven ineffective.
•
Local ketogenicrecipies are available and cost
effective.
Epilepsy Surgery
•
•

FDA approved surgical procedures:
Vagus nerve stimulation
Surgical treatment

•
•

Investigational:
Deep brain stimulation
Gene therapy

ETHOSUXIMIDE
*not available in Pakistan
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TPM
LEV
LTG
ZNS

INTRODUCTION

VIGABATRIN
#Avoid in myoclonus

Clinical situation
Absence
Myoclonic
VPA
VPA
ESM
LEV
ESM
LEV
LTG
TPM

KETOGENIC DIET

Table 10: Generalized Tonic Clonic Epilepsy – AEDs of choice

1st line

GTC
LPA
LTG
LTG
LEV
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•

Laser Ablation

Surgical Treatment
•
•
•
•
-

Upto 85% seizure-free rates
Resections:
lesionectomy, lobectomy, hemispherectomy
Disconnections:
Callosotomy, subpial transection, steriotactic
ablations
Augmentations:
Vagal, cerebellar, thalamic, deep brain stimulation

2.
3.
4.

All patients with focal onset seizures that are refractory
to an adequate trial of two or more AEDs of choice and
are refractory to treatment should be referred for phase
1 surgical evaluation to an epilepsy specialist. All
lesion-related Epilepsy syndromes should be
considered for surgical management

5.
6.
7.

SUMMARY:
These guidelines hope to highlight the problems that
exist in the care and management of epilepsy patients
like Patient and physician awareness , social and
cultural beliefs, easy access to treatment,misdiagnosis,
inappropriate
or
Inadequatetreatment,
sudden
unexpected death that might have been prevented,
preventable etiologies, Women with epilepsy, epilepsy
in children, epilepsy in the elderly, advice about
pregnancy and contraception and management of
status epilepticus in children and adults. These
guideline will be revisited and modified on applicability
every four years and it is vital that a spotlight is kept on
the need to further develop variable services for people
with epilepsy. The place of newly licensed drugs,
stigmas, and cost for epilepsy also needs careful
consideration. The primary scope of these guidelines
ofcourse is to provide a concise practical management
plan which considers the role of AEDs especially their
judicial use. The role of established and newly licensed
drugs is considered with comparison of cost effectiveness.
People with epilepsy remain at the centre of this
guideline, and the need for services to consider the
needs of each individual and their care givers have been
focused. Attention has been paid to ensure that the
recommendations are written in clear language and be
accessible, and, I hope, useful to all. We remain
committed to the care ofpeople with epilepsy and
commend these guidelines to you in that light.

8.
9.
10.

11.

12.

13.
14.
15.
16.
17.
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